A Phase I Trial Of Gemcitabine, 17-Allylaminogeldanamycin (17-AAG) And Cisplatin In Advanced Solid Tumor Patients
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Tanespimycin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker
- 04 Jun 2013 Biomarkers information updated
- 06 Jun 2012 Actual end date changed from Oct 2008 to Sep 2007 as reported by ClinicalTrials.gov.
- 14 Nov 2011 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.